PMID- 36217880 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230208 IS - 1096-9071 (Electronic) IS - 0146-6615 (Print) IS - 0146-6615 (Linking) VI - 95 IP - 1 DP - 2023 Jan TI - SARS-CoV-2 evolves to reduce but not abolish neutralizing action. PG - e28207 LID - 10.1002/jmv.28207 [doi] LID - e28207 AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) have prolonged coronavirus disease 2019 (COVID-19) pandemic by escaping pre-existing immunity acquired by natural infection or vaccination. Elucidation of VOCs' mutation trends and evasion of neutralization is required to update current control measures. Mutations and the prevalence of VOCs were analyzed in the global immunization coverage rate context. Lentivirus-based pseudovirus neutralization analysis platforms for SARS-CoV-2 prototype strain (PS) and VOCs, containing Alpha, Beta, Gamma, Delta, and Omicron, were constructed based on the spike protein of each variant and HEK 293T cell line expressing the human angiotensin-converting enzyme 2 (hACE2) receptor on the surface, and an enhanced green fluorescent protein reporter. Serum samples from 65 convalescent individuals and 20 WIBP-CorV vaccine recipients and four therapeutic monoclonal antibodies (mAbs) namely imdevimab, casirivimab, bamlanivimab, and etesevimab were used to evaluate the neutralization potency against the variants. Pseudovirus-based neutralization assay platforms for PS and VOCs were established, and multiplicity of infection (MOI) was the key factor influencing the assay result. Compared to PS, VOCs may enhance the infectivity of hACE2-293T cells. Except for Alpha, other VOCs escaped neutralization to varying degrees. Attributed to favorable and emerging mutations, the current pandemic Omicron variant of all VOCs demonstrated the most significant neutralization-escaping ability to the sera and mAbs. Compared with the PS pseudovirus, Omicron had 15.7- and 3.71-fold decreases in the NT50 value (the highest serum dilution corresponding to a neutralization rate of 50%); and correspondingly, 90% and 43% of immunization or convalescent serum samples lost their neutralizing activity against the Omicron variant, respectively. Therefore, SARS-CoV-2 has evolved persistently with a strong ability to escape neutralization and prevailing against the established immune barrier. Our findings provide important clues to controlling the COVID-19 pandemic caused by new variants. CI - (c) 2022 Wiley Periodicals LLC. FAU - Zhang, Yandi AU - Zhang Y AD - Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Ndzouboukou, Jo-Lewis B AU - Ndzouboukou JB AD - Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Lin, Xiaosong AU - Lin X AD - Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Hou, Hongyan AU - Hou H AD - Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Feng AU - Wang F AD - Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Yuan, Leyong AU - Yuan L AD - Department of Clinical Laboratory, Southern University of Science and Technology Hospital, Shenzhen, China. FAU - Gan, Mengze AU - Gan M AUID- ORCID: 0000-0002-9663-6737 AD - Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Yao, Zongjie AU - Yao Z AD - Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Fu, Hui AU - Fu H AD - Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Cao, Jinge AU - Cao J AD - Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Fan, Xionglin AU - Fan X AUID- ORCID: 0000-0001-9754-372X AD - Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221019 PL - United States TA - J Med Virol JT - Journal of medical virology JID - 7705876 RN - 0 (WIBP COVID-19 vaccine) RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Neutralizing) RN - 0 (Antibodies, Viral) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *SARS-CoV-2/genetics MH - *COVID-19/prevention & control MH - COVID-19 Serotherapy MH - Pandemics MH - Antibodies, Monoclonal MH - Antibodies, Neutralizing MH - Antibodies, Viral MH - Spike Glycoprotein, Coronavirus/genetics PMC - PMC9874811 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - VOCs OT - immune escape OT - neutralizing antibodies COIS- The authors declare no conflicts of interest. EDAT- 2022/10/12 06:00 MHDA- 2023/01/11 06:00 PMCR- 2022/10/19 CRDT- 2022/10/11 04:22 PHST- 2022/09/25 00:00 [revised] PHST- 2022/08/29 00:00 [received] PHST- 2022/10/02 00:00 [accepted] PHST- 2022/10/12 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/10/11 04:22 [entrez] PHST- 2022/10/19 00:00 [pmc-release] AID - JMV28207 [pii] AID - 10.1002/jmv.28207 [doi] PST - ppublish SO - J Med Virol. 2023 Jan;95(1):e28207. doi: 10.1002/jmv.28207. Epub 2022 Oct 19.